Current Insights on Lipid-Based Nanosystems
Lipid-based nanosystems, including solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), cationic lipid nanoparticles, nanoemulsions, and liposomes, have been extensively studied to improve drug delivery through different administration routes. The main advantages of these syste...
Saved in:
Other Authors: | , , |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_95900 | ||
005 | 20230105 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20230105s2022 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-6165-3 | ||
020 | |a 9783036561660 | ||
020 | |a 9783036561653 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-6165-3 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a TB |2 bicssc | |
100 | 1 | |a Silva, Ana Catarina |4 edt | |
700 | 1 | |a Moreira, João |4 edt | |
700 | 1 | |a Sousa Lobo, José Manuel |4 edt | |
700 | 1 | |a Silva, Ana Catarina |4 oth | |
700 | 1 | |a Moreira, João |4 oth | |
700 | 1 | |a Sousa Lobo, José Manuel |4 oth | |
245 | 1 | 0 | |a Current Insights on Lipid-Based Nanosystems |
260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
300 | |a 1 electronic resource (368 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a Lipid-based nanosystems, including solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), cationic lipid nanoparticles, nanoemulsions, and liposomes, have been extensively studied to improve drug delivery through different administration routes. The main advantages of these systems are their ability to protect, transport, and control the release of lipophilic and hydrophilic molecules (either small-molecular-weight molecules or macromolecules); the use of generally recognized as safe (GRAS) excipients that minimize the toxicity of the formulations; and the possibility to modulate pharmacokinetics and enable the site-specific delivery of encapsulated payloads. In addition, the versatility of lipid-based nanosystems has further been demonstrated for the delivery of vaccines, the protection of active cosmetic ingredients, and the improvement of moisturizing properties of cosmetic formulations.Lipid-based nanosystems are well established and there are already different commercially approved formulations for various human disorders. This success has paved the way for the diversification of the pipeline of development, to address unmet medical needs for several indications, such as cancer, neurological disorders, and autoimmune, genetic, and infectious diseases.This Special Issue aims to update readers on the latest research on lipid-based nanosystems, both at the preclinical and clinical levels. A series of 15 articles (six reviews and nine studies) is presented, with authors from 12 different countries, showing the globality of the investigations that are being carried out in this area. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Technology: general issues |2 bicssc | |
653 | |a Echinococcus granulosus | ||
653 | |a scolicidal | ||
653 | |a nanoliposome | ||
653 | |a juglone | ||
653 | |a apoptotic activity | ||
653 | |a hydrogel | ||
653 | |a SLNs | ||
653 | |a nose-to-brain delivery | ||
653 | |a mucoadhesion | ||
653 | |a quality by design | ||
653 | |a antioxidant activity | ||
653 | |a nasal administration | ||
653 | |a nanostructured lipid carriers | ||
653 | |a solid lipid nanoparticles | ||
653 | |a in vitro cell cultures | ||
653 | |a 3D nasal casts | ||
653 | |a lung cancer | ||
653 | |a targeted drug delivery | ||
653 | |a lipid-based nanocarriers | ||
653 | |a pulmonary delivery | ||
653 | |a dry powder inhalers | ||
653 | |a aerosols | ||
653 | |a liposomes | ||
653 | |a nanoemulsions | ||
653 | |a nanotechnology | ||
653 | |a biologically active compounds | ||
653 | |a dermal drug delivery | ||
653 | |a polyphenols | ||
653 | |a phytophenols | ||
653 | |a skin permeation | ||
653 | |a chemotherapy | ||
653 | |a radiotherapy | ||
653 | |a active targeting | ||
653 | |a passive targeting | ||
653 | |a tumor | ||
653 | |a immunoconjugate | ||
653 | |a traditional liposome | ||
653 | |a stealth liposome | ||
653 | |a triggered release | ||
653 | |a limitations of liposomes | ||
653 | |a drug transfer | ||
653 | |a in vitro release | ||
653 | |a colloidal drug carriers | ||
653 | |a lipid nanoparticles | ||
653 | |a hydrogel beads | ||
653 | |a cholesteryl nonanoate | ||
653 | |a bovine serum albumin | ||
653 | |a skin diseases | ||
653 | |a lipid-based nanosystems | ||
653 | |a cream | ||
653 | |a ointment | ||
653 | |a gel | ||
653 | |a pH-sensitive | ||
653 | |a liposome | ||
653 | |a imidazole | ||
653 | |a anticancer | ||
653 | |a drug delivery | ||
653 | |a multicellular spheroids | ||
653 | |a dapagliflozin | ||
653 | |a Box-Behnken design | ||
653 | |a FTIR | ||
653 | |a DSC | ||
653 | |a XRD | ||
653 | |a SEM | ||
653 | |a AFM | ||
653 | |a in vitro Franz diffusion cells | ||
653 | |a lipid-based nanoparticles | ||
653 | |a nanocarrier | ||
653 | |a surface charge | ||
653 | |a delivery systems | ||
653 | |a chronic treatment | ||
653 | |a mice | ||
653 | |a anti-oxidant activity | ||
653 | |a hepatoprotective effect | ||
653 | |a phospholipid | ||
653 | |a phytosomes | ||
653 | |a Silymarin | ||
653 | |a Colorectal Cancer | ||
653 | |a Niosomes | ||
653 | |a Oxaliplatin | ||
653 | |a Paclitaxel | ||
653 | |a d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) | ||
653 | |a therapeutic nucleic acids | ||
653 | |a schizophrenia | ||
653 | |a quetiapine fumarate | ||
653 | |a glycerosomes | ||
653 | |a central composite rotatable design | ||
653 | |a bioavailability | ||
653 | |a pharmacokinetic | ||
653 | |a n/a | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/6557 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/95900 |7 0 |z DOAB: description of the publication |